FDA approves Alzheimers drug Leqembi paving way for broader Medicare coverage

Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.

from Health and Science https://ift.tt/RzJIZud
https://ift.tt/Kotnp9J
https://ift.tt/etPodQj